Heron Therapeutics (HRTX) shares have risen sharply in trading today after the company announced that the FDA has approved SUSTOL (granisetron) extended-release injection for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. SUSTOL's long-acting formulation is based on the company's Biochronomer drug delivery technology which enables granisetron to remain in the body at therapeutic levels for at least five days with a single subcutaneous injection.